ALKS 7119

Drug Profile

ALKS 7119

Alternative Names: ALKS7119

Latest Information Update: 31 Aug 2016

Price : $50

At a glance

  • Originator Alkermes plc
  • Class Antidepressants; Nootropics
  • Mechanism of Action NMDA receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Agitation

Most Recent Events

  • 28 Aug 2016 Alkermes plans a phase I trial in Healthy volunteers in Netherlands (PO) (NTR5956)
  • 28 Apr 2016 Alkermes plans a phase I multiple ascending dose study in Agitation (In volunteers)
  • 25 Feb 2016 Alkermes has patent protection for ALKS 7119 in USA (Alkermes, Form 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top